Loading...
XLON
CEL
Market cap12mUSD
Jun 06, Last price  
10.00GBP
1D
-23.08%
1Q
-42.86%
IPO
-92.16%
Name

Celadon Pharmaceuticals PLC

Chart & Performance

D1W1MN
P/E
P/S
11,933.27
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
75k
+212.50%
002,00024,00075,000
Net income
-7m
L-58.99%
-151,697-1,398,945-4,783,000-17,411,000-7,140,000
CFO
-6m
L-2.10%
0-77,574-3,148,000-6,100,000-5,972,000
Earnings
Sep 29, 2025

Profile

Celadon Pharmaceuticals Plc, a pharmaceutical company, engages in the research, manufacture, and supply of cannabinoids for use in approved medicines. The company focuses on growing indoor hydroponic THC cannabis for use in medicinal products used to treat chronic pain. It also intends to conduct research into cannabinoids for use in chronic pain, as well as other conditions, such as autism and multiple sclerosis. The company was founded in 2018 and is headquartered in London, the United Kingdom.
IPO date
Oct 19, 2018
Employees
24
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑12
Income
Revenues
75
212.50%
24
1,100.00%
Cost of revenue
90
Unusual Expense (Income)
NOPBT
75
(66)
NOPBT Margin
100.00%
Operating Taxes
(261)
(707)
Tax Rate
NOPAT
336
641
Net income
(7,140)
-58.99%
(17,411)
264.02%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,976
7,491
BB yield
Debt
Debt current
74
66
Long-term debt
9,326
9,164
Deferred revenue
Other long-term liabilities
405
389
Net debt
7,923
3,951
Cash flow
Cash from operating activities
(5,972)
(6,100)
CAPEX
(341)
(2,086)
Cash from investing activities
(341)
1,390
Cash from financing activities
2,511
5,948
FCF
189
6,599
Balance
Cash
1,259
5,061
Long term investments
218
218
Excess cash
1,473
5,278
Stockholders' equity
(22,323)
(21,398)
Invested Capital
30,626
33,365
ROIC
1.05%
2.67%
ROCE
0.90%
EV
Common stock shares outstanding
61,894
57,295
Price
Market cap
EV
EBITDA
609
400
EV/EBITDA
Interest
598
4,040
Interest/NOPBT
797.33%